Bortezomib

Product NDC
68083-650
11-digit product format
680830650
Labeler code
68083
Product ID
68083-650_81bfe4b3-5e07-442f-9351-f521de933404
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
Bortezomib
Dosage form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route
INTRAVENOUS; SUBCUTANEOUS
Labeler
Gland Pharma Limited
Application
ANDA219167
Marketing category
ANDA
Marketing start
2026-01-06
Substance
BORTEZOMIB
Active strength
1 mg/1
Pharmacologic classes
Proteasome Inhibitor [EPC], Proteasome Inhibitors [MoA]
NDC exclude flag
No
Listing certified through
2027-12-31
Current FDA listing
Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 42.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A219167-001BORTEZOMIBBORTEZOMIB1MG/VIALPOWDER / INTRAVENOUS, SUBCUTANEOUSAP2026-01-06
A219167-002BORTEZOMIBBORTEZOMIB2.5MG/VIALPOWDER / INTRAVENOUS, SUBCUTANEOUSAP2026-01-06

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 2 matching rows.

Application-product, TE code table
Application-productTE code
A219167-001AP
A219167-002AP

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-08-18 06:07:402026-07A219167-001BORTEZOMIB1MG/VIALPOWDER / INTRAVENOUS, SUBCUTANEOUSAP2026-01-06caaa826d4ba7…
2026-08-18 06:07:402026-07A219167-002BORTEZOMIB2.5MG/VIALPOWDER / INTRAVENOUS, SUBCUTANEOUSAP2026-01-06caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A219167-001BORTEZOMIB1MG/VIALPOWDER / INTRAVENOUS, SUBCUTANEOUSAP2026-01-06011fe1cb6892…
2026-02-19 14:30 UTC2026-02A219167-002BORTEZOMIB2.5MG/VIALPOWDER / INTRAVENOUS, SUBCUTANEOUSAP2026-01-06011fe1cb6892…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A219167-001BORTEZOMIB1MG/VIALPOWDER / INTRAVENOUS, SUBCUTANEOUSAP2026-01-06a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A219167-002BORTEZOMIB2.5MG/VIALPOWDER / INTRAVENOUS, SUBCUTANEOUSAP2026-01-06a50c72e98297…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-08-18 06:07:402026-07A219167-001AP1caaa826d4ba7…
2026-08-18 06:07:402026-07A219167-002AP1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A219167-001AP1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A219167-002AP1011fe1cb6892…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A219167-001AP1a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A219167-002AP1a50c72e98297…

Additional Listing Data#

Finished product
Yes
Brand name base
Bortezomib
Listing expiration
2027-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
BORTEZOMIB1 mg/1

Harmonized UNII identifiers#

UNII identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
69G8BD63PPInternal UNII lookup

Harmonized RxCUI identifiers#

RxCUI identifiers page 1 of 1 · 2 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
2601542Internal RxNorm lookup
2601544Internal RxNorm lookup

Harmonized SPL set identifiers#

SPL set identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
cd698074-da21-4b53-8f6b-241535a8d598Available on FDA.report

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
b069d653-565d-b331-cf82-116aa266aee9Product name420260317
987023d7-918d-4465-be3c-f3f8f784679bProduct name120250318
2cff6375-aa9a-4194-a1db-33f6ed6564f1Product name120230322
f8ade071-6be1-4cb3-a390-e8ba41353f9bProduct name120230322
c3c5823c-3bc3-46c2-bc6a-295b30affa78Product name120230113
6429b384-c989-4e27-bc69-c5e1c7dc2e31Product name120200304
71c1111b-030c-4ada-94cb-bf623cfad8ecProduct name120180108

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
68083-650-01Bortezomib1 in 1 VIAL, SINGLE-DOSEINJECTION, POWDER, LYOPHILIZED,14
68083-650-01Bortezomib1 in 1 CARTONINJECTION, POWDER, LYOPHILIZED,14

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
BortezomibBORTEZOMIBGland Pharma Limitedcd698074-da21-4b53-8f6b-241535a8d5982026-01-08Warnings, Adverse reactionsExact identifier
application applno (ANDA): 219167
application number: ANDA219167
ndc (product): 68083-650

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
2601542bortezomib 1 MG InjectionPSNcd698074-da21-4b53-8f6b-241535a8d5984
2601544bortezomib 2.5 MG InjectionPSNcd698074-da21-4b53-8f6b-241535a8d5984
2601542bortezomib 1 MG InjectionSCDcd698074-da21-4b53-8f6b-241535a8d5984
2601544bortezomib 2.5 MG InjectionSCDcd698074-da21-4b53-8f6b-241535a8d5984

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionMarketing startSampleExclude flagStatus
68083-650-01680830650011 VIAL, SINGLE-DOSE in 1 CARTON (68083-650-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE2026-01-06NoNoCurrent